RSNA 2019: AI, Machine Learning Continue To Dominate Developments In Radiology

 
• By Phil Greenfield

Artificial intelligence (AI) and machine learning took center stage at this year’s Radiological Society of North America meeting in Chicago, and the pervasiveness of AI tech in new product launches was further emphasized at the RSNA’s expanded AI Showcase exhibit.

Tech Exhibit Floor 2018

At last year’s RSNA, Siemens Healthineers AG debuted its first AI-based software assistant for radiology, the AI-Rad Companion Chest CT, which automates enhanced visualization of CT images of the lungs, heart and aorta. This year, the company added two more AI-based software assistants that are designed to free radiologists from the burden of performing routine activities during magnetic resonance imaging (MRI) examinations of the brain and prostate.

AI-Rad Companion Prostate MR for Biopsy Support automatically segments the outer contour of the prostate, which can cut the time...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

More from Digital Technologies

Veterinary Heart Health Goes High-Tech: Eko And Boehringer Use AI To Spot Heart Murmurs In Dogs

 
• By Marion Webb

Eko hopes its new partnership with Boehringer Ingelheim to develop algorithms for accurately detecting heart murmurs in dogs will pave the way for more collaborations with medical and pharmaceutical companies to advance early detection in humans as well as animals.

Prix Galien Spotlights Mental Health ‘Renaissance’ But Systemic Hurdles Persist

 
• By Natasha Barrow

Experts at the Prix Galien UK Forum discussed the future of mental health innovation, emphasizing the important roles of digital solutions, diagnostic biomarkers and community involvement.

With LDT Rule DOA, Could FDA Shift Focus To RUOs?

 
• By Brian Bossetta

Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?